Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 692 | 1.090 |
Why?
|
| Obesity | 10 | 2021 | 1232 | 0.900 |
Why?
|
| Leptin | 4 | 2024 | 85 | 0.840 |
Why?
|
| Bone and Bones | 2 | 2024 | 142 | 0.630 |
Why?
|
| Hyperglycemia | 1 | 2020 | 104 | 0.630 |
Why?
|
| Glucocorticoids | 2 | 2020 | 188 | 0.620 |
Why?
|
| Primary Prevention | 1 | 2017 | 136 | 0.510 |
Why?
|
| Juglans | 3 | 2021 | 11 | 0.480 |
Why?
|
| Health Status | 1 | 2017 | 433 | 0.460 |
Why?
|
| Follistatin | 3 | 2021 | 44 | 0.460 |
Why?
|
| Anti-Obesity Agents | 3 | 2019 | 14 | 0.450 |
Why?
|
| Nephrosis | 1 | 2013 | 3 | 0.430 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 7 | 0.430 |
Why?
|
| Diabetes Complications | 1 | 2014 | 106 | 0.430 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 686 | 0.420 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 48 | 0.410 |
Why?
|
| Risk Assessment | 1 | 2020 | 2055 | 0.400 |
Why?
|
| Hospitalization | 1 | 2020 | 1347 | 0.400 |
Why?
|
| Energy Metabolism | 4 | 2024 | 379 | 0.360 |
Why?
|
| Neurosecretory Systems | 2 | 2024 | 24 | 0.340 |
Why?
|
| Weight Loss | 3 | 2019 | 272 | 0.300 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 2 | 2018 | 5 | 0.290 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2018 | 7 | 0.290 |
Why?
|
| Blood Glucose | 3 | 2020 | 485 | 0.290 |
Why?
|
| Benzazepines | 2 | 2019 | 21 | 0.280 |
Why?
|
| Activins | 2 | 2018 | 54 | 0.280 |
Why?
|
| Fibronectins | 2 | 2017 | 43 | 0.280 |
Why?
|
| Insulin Resistance | 3 | 2021 | 410 | 0.270 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 57 | 0.260 |
Why?
|
| Double-Blind Method | 7 | 2021 | 739 | 0.230 |
Why?
|
| Humans | 25 | 2024 | 62965 | 0.230 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 309 | 0.220 |
Why?
|
| Autoantibodies | 2 | 2016 | 182 | 0.210 |
Why?
|
| Food Preferences | 2 | 2021 | 51 | 0.200 |
Why?
|
| Stroke Volume | 1 | 2024 | 331 | 0.200 |
Why?
|
| Middle Aged | 14 | 2024 | 17429 | 0.200 |
Why?
|
| Female | 18 | 2024 | 32619 | 0.190 |
Why?
|
| Homeostasis | 1 | 2024 | 368 | 0.190 |
Why?
|
| Fasting | 2 | 2019 | 51 | 0.180 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2021 | 6 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2450 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2021 | 13 | 0.180 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 911 | 0.170 |
Why?
|
| Male | 16 | 2024 | 29620 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 74 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 216 | 0.170 |
Why?
|
| Risk Factors | 3 | 2020 | 5318 | 0.170 |
Why?
|
| Body Weight | 2 | 2019 | 377 | 0.170 |
Why?
|
| Gastrointestinal Hormones | 1 | 2019 | 10 | 0.160 |
Why?
|
| Liraglutide | 1 | 2019 | 4 | 0.160 |
Why?
|
| Metabolic Syndrome | 2 | 2017 | 143 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 59 | 0.150 |
Why?
|
| Eating | 1 | 2019 | 138 | 0.150 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 122 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 85 | 0.150 |
Why?
|
| Follistatin-Related Proteins | 1 | 2018 | 22 | 0.150 |
Why?
|
| Reproduction | 1 | 2018 | 92 | 0.140 |
Why?
|
| Appetite Regulation | 1 | 2017 | 8 | 0.140 |
Why?
|
| Nuts | 1 | 2017 | 6 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 505 | 0.140 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2017 | 9 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 1734 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2016 | 164 | 0.140 |
Why?
|
| Functional Food | 1 | 2017 | 37 | 0.140 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Heart Failure | 1 | 2024 | 904 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 161 | 0.130 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 50 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 152 | 0.130 |
Why?
|
| White Matter | 1 | 2017 | 123 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2017 | 187 | 0.130 |
Why?
|
| Incidence | 1 | 2020 | 1374 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 258 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 523 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1116 | 0.120 |
Why?
|
| Aged | 6 | 2024 | 14300 | 0.120 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 161 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6565 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 1119 | 0.110 |
Why?
|
| WT1 Proteins | 1 | 2013 | 6 | 0.110 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 16 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 265 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 43 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 1365 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 331 | 0.100 |
Why?
|
| Cues | 3 | 2019 | 76 | 0.100 |
Why?
|
| Animals | 4 | 2024 | 20643 | 0.100 |
Why?
|
| Felty Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 832 | 0.090 |
Why?
|
| Neurons | 1 | 2017 | 920 | 0.090 |
Why?
|
| Brain | 2 | 2017 | 1555 | 0.090 |
Why?
|
| Young Adult | 3 | 2018 | 4660 | 0.090 |
Why?
|
| Postprandial Period | 2 | 2019 | 18 | 0.080 |
Why?
|
| Histones | 1 | 2011 | 482 | 0.070 |
Why?
|
| United States | 1 | 2020 | 7756 | 0.070 |
Why?
|
| Energy Intake | 2 | 2019 | 171 | 0.070 |
Why?
|
| Cognition | 2 | 2019 | 481 | 0.060 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2018 | 207 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 968 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 864 | 0.050 |
Why?
|
| Adult | 5 | 2019 | 16692 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2562 | 0.040 |
Why?
|
| Glicentin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxyntomodulin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Peptide YY | 1 | 2019 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Reward | 1 | 2019 | 87 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2019 | 83 | 0.040 |
Why?
|
| Breakfast | 1 | 2017 | 1 | 0.040 |
Why?
|
| Satiety Response | 1 | 2017 | 5 | 0.040 |
Why?
|
| Creatine | 1 | 2017 | 24 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2154 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 98 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 74 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 121 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Lipids | 1 | 2019 | 316 | 0.030 |
Why?
|
| Azathioprine | 1 | 2016 | 27 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 251 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 377 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 30 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1082 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 302 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 147 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 200 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 87 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 104 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 205 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 348 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 464 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 976 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 377 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 223 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1253 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 381 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1389 | 0.030 |
Why?
|
| Aging | 1 | 2017 | 745 | 0.020 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 26 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 537 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2555 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1545 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 137 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3266 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 940 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 376 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 332 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 5424 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 6205 | 0.010 |
Why?
|